Skip to content

Study · Randomized controlled trial · n = 225 · 2026

12 results

Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT-J trial.

Yokote K, Fukushima Y, Shingaki T, Oura T, Ogawa W

Diabetes, obesity & metabolism25 Nov 2025Cited by 5 (Europe PMC)

PMID41290555 (opens in a new tab)PMCIDPMC12803658 (opens in a new tab)DOI10.1111/dom.70315 (opens in a new tab)PepBankPUB-41290555
Read at sourcePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with obesity disease, weight reduction at week 72 with tirzepatide was generally similar across subgroups.

    In plain wordsIn Japanese adults with obesity disease, tirzepatide weight loss was generally similar across subgroups.

    Peptide
    Tirzepatide
    Outcome
    No significant changeWeight reduction across subgroups at week 72
    Study

    n = 225

    Comparator
    Other baseline subgroups
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 mg and 15 mg · subcutaneous · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Weight reduction at week 72 was generally similar across subgroups.
    1 context sentence
    Summary · context
    Japanese adults with obesity disease, excluding diabetes, were randomised 1:1:1 to receive once-weekly subcutaneous tirzepatide 10 mg, tirzepatide 15 mg, or placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with obesity disease, 86%-100% of tirzepatide participants achieved weight reduction of 5% or more versus 18%-30% with placebo across subgroups.

    In plain wordsIn Japanese adults with obesity disease, far more people on tirzepatide than on placebo lost at least 5% of weight.

    Peptide
    Tirzepatide
    Outcome
    IncreaseWeight reduction of 5% or more across subgroups
    Study

    n = 225

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 mg and 15 mg · subcutaneous · 72 weeksAs given in this study (human).

    Measurements

    responders
    86 to 100%
    tirzepatide
    responders
    18 to 30%
    placebo

    Source sentences

    Summary
    Higher proportions of participants achieved ≥5% weight reduction following week 72 of tirzepatide (86%-100%) compared with placebo (18%-30%) across subgroups
    1 context sentence
    Summary · context
    Japanese adults with obesity disease, excluding diabetes, were randomised 1:1:1 to receive once-weekly subcutaneous tirzepatide 10 mg, tirzepatide 15 mg, or placebo.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with obesity disease, all subgroups showed improvements in cardiometabolic parameters with tirzepatide.

    In plain wordsIn Japanese adults with obesity disease, heart and metabolic measures improved with tirzepatide in all subgroups.

    Peptide
    Tirzepatide
    Outcome
    MixedCardiometabolic parameters across subgroups
    Study

    n = 225

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 mg and 15 mg · subcutaneous · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    all subgroups showed improvements in cardiometabolic parameters with tirzepatide.
    2 context sentences
    Summary · context
    Post hoc analyses were conducted to examine cardiometabolic parameters by subgroup.
    Summary · context
    Japanese adults with obesity disease, excluding diabetes, were randomised 1:1:1 to receive once-weekly subcutaneous tirzepatide 10 mg, tirzepatide 15 mg, or placebo.
  4. 04HumanRandomized controlled trialSafety outcome

    In Japanese adults with obesity disease, safety profiles with tirzepatide did not substantially differ by subgroup.

    In plain wordsIn Japanese adults with obesity disease, tirzepatide safety did not differ much between subgroups.

    Peptide
    Tirzepatide
    Outcome
    No significant changeSafety profile across subgroups
    Study

    n = 225

    Comparator
    Other baseline subgroups
    Outcome group
    Adverse events · Whole body
    Studied dose
    10 mg and 15 mg · subcutaneous · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Safety profiles did not substantially differ by subgroup.
    1 context sentence
    Summary · context
    Japanese adults with obesity disease, excluding diabetes, were randomised 1:1:1 to receive once-weekly subcutaneous tirzepatide 10 mg, tirzepatide 15 mg, or placebo.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In Japanese females with obesity disease, tirzepatide 10 mg reduced body weight by 17.5% versus placebo at week 72 (numerical, versus 15.1% in males).

    In plain wordsIn Japanese women with obesity disease, tirzepatide 10 mg reduced weight more than placebo, numerically more than in men.

    Peptide
    Tirzepatide
    Outcome
    DecreasePercent body weight reduction in females, 10 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 mg · subcutaneous · 72 weeksAs given in this study (human).

    Measurements

    estimated treatment difference
    −17.5%
    females, 10 mg

    Source sentences

    Summary
    Numerically greater reductions in percent body weight at week 72 were observed in females (estimated treatment differences: 10 mg, -17.5%; 15 mg, -24.9%) compared with males (10 mg, -15.1%; 15 mg, -18.1%)
    1 context sentence
    Summary · context
    Japanese adults with obesity disease, excluding diabetes, were randomised 1:1:1 to receive once-weekly subcutaneous tirzepatide 10 mg, tirzepatide 15 mg, or placebo.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In Japanese females with obesity disease, tirzepatide 15 mg reduced body weight by 24.9% versus placebo at week 72 (numerical, versus 18.1% in males).

    In plain wordsIn Japanese women with obesity disease, tirzepatide 15 mg reduced weight more than placebo, numerically more than in men.

    Peptide
    Tirzepatide
    Outcome
    DecreasePercent body weight reduction in females, 15 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    15 mg · subcutaneous · 72 weeksAs given in this study (human).

    Measurements

    estimated treatment difference
    −24.9%
    females, 15 mg

    Source sentences

    Summary
    Numerically greater reductions in percent body weight at week 72 were observed in females (estimated treatment differences: 10 mg, -17.5%; 15 mg, -24.9%) compared with males (10 mg, -15.1%; 15 mg, -18.1%)
    1 context sentence
    Summary · context
    Japanese adults with obesity disease, excluding diabetes, were randomised 1:1:1 to receive once-weekly subcutaneous tirzepatide 10 mg, tirzepatide 15 mg, or placebo.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In Japanese males with obesity disease, tirzepatide 10 mg reduced body weight by 15.1% versus placebo at week 72.

    In plain wordsIn Japanese men with obesity disease, tirzepatide 10 mg reduced weight more than placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreasePercent body weight reduction in males, 10 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 mg · subcutaneous · 72 weeksAs given in this study (human).

    Measurements

    estimated treatment difference
    −15.1%
    males, 10 mg

    Source sentences

    Summary
    Numerically greater reductions in percent body weight at week 72 were observed in females (estimated treatment differences: 10 mg, -17.5%; 15 mg, -24.9%) compared with males (10 mg, -15.1%; 15 mg, -18.1%)
    1 context sentence
    Summary · context
    Japanese adults with obesity disease, excluding diabetes, were randomised 1:1:1 to receive once-weekly subcutaneous tirzepatide 10 mg, tirzepatide 15 mg, or placebo.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In Japanese males with obesity disease, tirzepatide 15 mg reduced body weight by 18.1% versus placebo at week 72.

    In plain wordsIn Japanese men with obesity disease, tirzepatide 15 mg reduced weight more than placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreasePercent body weight reduction in males, 15 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    15 mg · subcutaneous · 72 weeksAs given in this study (human).

    Measurements

    estimated treatment difference
    −18.1%
    males, 15 mg

    Source sentences

    Summary
    Numerically greater reductions in percent body weight at week 72 were observed in females (estimated treatment differences: 10 mg, -17.5%; 15 mg, -24.9%) compared with males (10 mg, -15.1%; 15 mg, -18.1%)
    1 context sentence
    Summary · context
    Japanese adults with obesity disease, excluding diabetes, were randomised 1:1:1 to receive once-weekly subcutaneous tirzepatide 10 mg, tirzepatide 15 mg, or placebo.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with obesity disease and BMI below 35, tirzepatide 10 mg reduced body weight by 18.7% versus placebo at week 72.

    In plain wordsIn Japanese adults with obesity disease and lower BMI, tirzepatide 10 mg reduced weight more than placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreasePercent body weight reduction in BMI below 35, 10 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 mg · subcutaneous · 72 weeksAs given in this study (human).

    Measurements

    estimated treatment difference
    −18.7%
    BMI <35, 10 mg

    Source sentences

    Summary
    and in the BMI 2 subgroup (10 mg, -18.7%; 15 mg, -21.7%) compared with the BMI ≥35 kg/m2 subgroup (10 mg, -11.7%; 15 mg, -20.4%) with tirzepatide compared with placebo.
    1 context sentence
    Summary · context
    Japanese adults with obesity disease, excluding diabetes, were randomised 1:1:1 to receive once-weekly subcutaneous tirzepatide 10 mg, tirzepatide 15 mg, or placebo.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with obesity disease and BMI below 35, tirzepatide 15 mg reduced body weight by 21.7% versus placebo at week 72.

    In plain wordsIn Japanese adults with obesity disease and lower BMI, tirzepatide 15 mg reduced weight more than placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreasePercent body weight reduction in BMI below 35, 15 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    15 mg · subcutaneous · 72 weeksAs given in this study (human).

    Measurements

    estimated treatment difference
    −21.7%
    BMI <35, 15 mg

    Source sentences

    Summary
    and in the BMI 2 subgroup (10 mg, -18.7%; 15 mg, -21.7%) compared with the BMI ≥35 kg/m2 subgroup (10 mg, -11.7%; 15 mg, -20.4%) with tirzepatide compared with placebo.
    1 context sentence
    Summary · context
    Japanese adults with obesity disease, excluding diabetes, were randomised 1:1:1 to receive once-weekly subcutaneous tirzepatide 10 mg, tirzepatide 15 mg, or placebo.
  11. 11HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with obesity disease and BMI of 35 or above, tirzepatide 10 mg reduced body weight by 11.7% versus placebo at week 72.

    In plain wordsIn Japanese adults with obesity disease and higher BMI, tirzepatide 10 mg reduced weight more than placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreasePercent body weight reduction in BMI 35 or above, 10 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 mg · subcutaneous · 72 weeksAs given in this study (human).

    Measurements

    estimated treatment difference
    −11.7%
    BMI >=35, 10 mg

    Source sentences

    Summary
    and in the BMI 2 subgroup (10 mg, -18.7%; 15 mg, -21.7%) compared with the BMI ≥35 kg/m2 subgroup (10 mg, -11.7%; 15 mg, -20.4%) with tirzepatide compared with placebo.
    1 context sentence
    Summary · context
    Japanese adults with obesity disease, excluding diabetes, were randomised 1:1:1 to receive once-weekly subcutaneous tirzepatide 10 mg, tirzepatide 15 mg, or placebo.
  12. 12HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with obesity disease and BMI of 35 or above, tirzepatide 15 mg reduced body weight by 20.4% versus placebo at week 72.

    In plain wordsIn Japanese adults with obesity disease and higher BMI, tirzepatide 15 mg reduced weight more than placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreasePercent body weight reduction in BMI 35 or above, 15 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    15 mg · subcutaneous · 72 weeksAs given in this study (human).

    Measurements

    estimated treatment difference
    −20.4%
    BMI >=35, 15 mg

    Source sentences

    Summary
    and in the BMI 2 subgroup (10 mg, -18.7%; 15 mg, -21.7%) compared with the BMI ≥35 kg/m2 subgroup (10 mg, -11.7%; 15 mg, -20.4%) with tirzepatide compared with placebo.
    1 context sentence
    Summary · context
    Japanese adults with obesity disease, excluding diabetes, were randomised 1:1:1 to receive once-weekly subcutaneous tirzepatide 10 mg, tirzepatide 15 mg, or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT04844918

A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease

Eli Lilly and Companyn = 26710 May 2021 to 24 Jun 2023

Obesity

Trial pageClinicalTrials.govUpdated 16 Jul 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.